Explore

Rapid Read Rapid Read
FDA to Review Controversial Peptides Amid Rising Demand and Safety Concerns

FDA to Review Controversial Peptides Amid Rising Demand and Safety Concerns

The FDA is set to review the safety and efficacy of seven peptides, which have gained popularity for their purported wellness benefits, including sleep, muscle growth, and anti-aging. The Pharmacy Compounding Advisory Committee will meet to decide if these peptides can be produced by licensed compounding pharmacies. Despite their popularity, the FDA has raised concerns about the lack of substantial evidence supporting their safety and effectiveness. The review comes as peptides have been promoted by influencers and figures like Health Secretary Robert F. Kennedy Jr., who has advocated for their benefits. The FDA's decision will be influenced by the committee's recommendations, although these are not binding.
Rapid Read Rapid Read
FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

FDA Advisory Committee Votes on Peptide BPC-157 Amid Safety Concerns

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has voted 8-6, with one abstention, to add the peptide BPC-157 to a drug compounding list, moving it closer to legal availability with a prescription. This decision is part of a broader review of seven peptides, which have gained popularity for purported health benefits like muscle building and metabolism improvement. Despite the vote, the decision is non-binding and requires FDA approval. The committee's consideration of an atypical regulatory pathway for these peptides has sparked debate, as there is limited human clinical trial data supporting their safety and effectiveness. Health Secretary Robert F. Kennedy Jr. has promoted peptide use, but the process has faced criticism over potential conflicts of interest among committee members.
Rapid Read Rapid Read
FDA to Review Controversial Peptides Amid Rising Popularity and Safety Concerns

FDA to Review Controversial Peptides Amid Rising Popularity and Safety Concerns

The U.S. Food and Drug Administration (FDA) is set to review the safety and efficacy of seven peptides that have gained popularity for their purported health benefits, such as muscle growth and anti-aging. These compounds have been promoted by social media influencers and endorsed by Health Secretary Robert F. Kennedy Jr. Despite their popularity, the FDA has raised concerns about the lack of evidence supporting their safety and effectiveness. The review will determine whether these peptides can be made available through licensed pharmacies, potentially impacting their regulation and availability.
AP News AP News
FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

Federal health advisers are meeting to review a group of controversial chemicals called peptides
AP News AP News
FDA reviews peptide injections favored by RFK Jr. and wellness influencers

FDA reviews peptide injections favored by RFK Jr. and wellness influencers

Federal health advisers are meeting to review a group of controversial chemicals called peptides
AP News AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

Federal health advisers are recommending broader access to controversial chemicals called peptides
Rapid Read Rapid Read
FDA Panel Recommends Easing Restrictions on Peptide Drugs Amid Safety Concerns

FDA Panel Recommends Easing Restrictions on Peptide Drugs Amid Safety Concerns

A panel of federal health advisers has recommended that the Food and Drug Administration (FDA) ease restrictions on several peptides, which are popular among wellness influencers and celebrities. These peptides, including BPC-157, TB-500, and KPV, are currently restricted from being produced by pharmacies due to safety concerns. The panel's decision, which was made by a narrow vote of 8-6 with one abstention, suggests adding these peptides to the FDA's list of substances considered safe for pharmacy compounding. This recommendation comes despite warnings from FDA scientists about the lack of evidence supporting the safety and efficacy of these peptides. The panel included several members with ties to the peptide industry, which has raised concerns about the influence of market demand over scientific evidence.
Rapid Read Rapid Read
FDA Committee Rejects Emideltide for Compounding, Citing Safety Concerns

FDA Committee Rejects Emideltide for Compounding, Citing Safety Concerns

An FDA advisory committee has declined to recommend the peptide Emideltide for legal compounding and sale by pharmacies. This decision comes after previous votes to loosen restrictions on unapproved products, a move supported by U.S. Health Secretary Robert F. Kennedy Jr. Emideltide is being evaluated for its potential use in treating opioid withdrawal and insomnia. The committee's decision reflects concerns about the safety and efficacy of the peptide, despite some members advocating for its role in individualized patient care. The FDA will consider the committee's advice in its final decision.
Rapid Read Rapid Read
FDA Panel Supports Easier Access to Peptide Therapies Despite Safety Concerns

FDA Panel Supports Easier Access to Peptide Therapies Despite Safety Concerns

An advisory panel to the Food and Drug Administration (FDA) has recommended easing restrictions on peptide therapies, allowing specialized pharmacies to produce these compounds. Despite the FDA scientists' concerns about the lack of large-scale human trials and potential safety risks, the panel voted in favor of making peptides more accessible. The decision was influenced by the growing demand for peptides in athletic performance and longevity, as well as the need to regulate the unvetted substances currently available in the market. Health Secretary Robert F. Kennedy Jr. has publicly supported this move, emphasizing the importance of safe manufacturing processes.
Rapid Read Rapid Read
FDA Committee to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

FDA Committee to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

A committee from the Food and Drug Administration (FDA) is set to review the safety and efficacy of synthetic peptides, which have gained popularity among fitness enthusiasts and individuals seeking alternative treatments for chronic conditions. Despite the human body naturally producing peptides like insulin and oxytocin, many synthetic variants have not received FDA approval, raising concerns about their safety and effectiveness. The upcoming FDA meeting will focus on seven commonly used peptides, as scientists and health experts express caution over their unregulated use.
Reuters Reuters
FDA panel to review popular peptides amid persistent consumer appetite

FDA panel to review popular peptides amid persistent consumer appetite

By Sneha S K and Sriparna Roy July 22 (Reuters) - U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry participants say consumer demand is likely to remain strong.
Rapid Read Rapid Read
FDA to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

FDA to Review Safety and Efficacy of Synthetic Peptides Amid Growing Hype

The FDA is set to review the safety and efficacy of synthetic peptides, which have gained popularity among fitness enthusiasts and those seeking new treatments for chronic conditions. While the human body naturally produces peptides like insulin, many synthetic versions are not FDA-approved, raising concerns about their safety. The upcoming FDA meeting will discuss seven commonly used peptides, as scientists express worries about the potential risks associated with unregulated use.